Ginell Post
Concepts (259)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hodgkin Disease | 3 | 2019 | 45 | 1.070 |
Why?
| Plasma Cells | 4 | 2018 | 223 | 0.850 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 4 | 2024 | 105 | 0.850 |
Why?
| Epidural Neoplasms | 1 | 2019 | 4 | 0.700 |
Why?
| ABO Blood-Group System | 1 | 2019 | 15 | 0.700 |
Why?
| Spinal Cord Compression | 1 | 2019 | 10 | 0.700 |
Why?
| von Willebrand Factor | 1 | 2019 | 42 | 0.690 |
Why?
| Monocytes | 1 | 2019 | 132 | 0.660 |
Why?
| Pseudolymphoma | 1 | 2018 | 4 | 0.650 |
Why?
| Scalp Dermatoses | 1 | 2018 | 5 | 0.650 |
Why?
| Pulmonary Embolism | 1 | 2019 | 97 | 0.630 |
Why?
| Antigens, CD | 1 | 2019 | 215 | 0.630 |
Why?
| Tumor Microenvironment | 1 | 2019 | 210 | 0.620 |
Why?
| Hematologic Neoplasms | 1 | 2019 | 99 | 0.620 |
Why?
| Blood Coagulation Tests | 1 | 2017 | 19 | 0.610 |
Why?
| Optics and Photonics | 1 | 2017 | 12 | 0.610 |
Why?
| Endemic Diseases | 1 | 2017 | 22 | 0.600 |
Why?
| Diagnostic Tests, Routine | 1 | 2017 | 29 | 0.600 |
Why?
| Immunoglobulins | 1 | 2017 | 79 | 0.580 |
Why?
| Histoplasmosis | 1 | 2017 | 50 | 0.580 |
Why?
| Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 6 | 0.500 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2015 | 7 | 0.500 |
Why?
| Interleukin-6 | 1 | 2016 | 264 | 0.500 |
Why?
| Antifungal Agents | 1 | 2017 | 339 | 0.490 |
Why?
| Leukemoid Reaction | 1 | 2014 | 6 | 0.490 |
Why?
| Muscle Neoplasms | 1 | 2014 | 17 | 0.490 |
Why?
| Liposarcoma | 1 | 2014 | 22 | 0.480 |
Why?
| Receptors, Adrenergic, alpha-1 | 3 | 2003 | 14 | 0.460 |
Why?
| Neoplasms, Second Primary | 1 | 2014 | 69 | 0.460 |
Why?
| Lymphoma | 3 | 2024 | 65 | 0.460 |
Why?
| Sarcoma | 1 | 2014 | 67 | 0.450 |
Why?
| Neutrophils | 1 | 2014 | 137 | 0.450 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.420 |
Why?
| Fetomaternal Transfusion | 1 | 2012 | 3 | 0.420 |
Why?
| Plasma Exchange | 1 | 2012 | 23 | 0.420 |
Why?
| Humans | 30 | 2024 | 49827 | 0.420 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2012 | 24 | 0.410 |
Why?
| Cell Differentiation | 1 | 2015 | 653 | 0.400 |
Why?
| Liver | 1 | 2017 | 1109 | 0.400 |
Why?
| Graft vs Host Disease | 1 | 2011 | 74 | 0.360 |
Why?
| Myeloproliferative Disorders | 1 | 2010 | 27 | 0.360 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2011 | 252 | 0.350 |
Why?
| Bone Neoplasms | 1 | 2011 | 179 | 0.340 |
Why?
| Liver Transplantation | 1 | 2011 | 150 | 0.330 |
Why?
| Translocation, Genetic | 1 | 2010 | 264 | 0.320 |
Why?
| Multiple Myeloma | 4 | 2019 | 2910 | 0.320 |
Why?
| Phenotype | 2 | 2019 | 727 | 0.280 |
Why?
| Pancytopenia | 3 | 2011 | 37 | 0.270 |
Why?
| Immunohistochemistry | 3 | 2017 | 971 | 0.250 |
Why?
| Male | 12 | 2022 | 25093 | 0.250 |
Why?
| Female | 11 | 2022 | 26329 | 0.240 |
Why?
| Guanine Nucleotide Exchange Factors | 2 | 2013 | 17 | 0.230 |
Why?
| Lymph Nodes | 2 | 2016 | 264 | 0.230 |
Why?
| Macrophages | 2 | 2019 | 364 | 0.220 |
Why?
| Diagnosis, Differential | 3 | 2018 | 1036 | 0.220 |
Why?
| Peptide Hydrolases | 2 | 2014 | 62 | 0.220 |
Why?
| Heterotrimeric GTP-Binding Proteins | 1 | 2002 | 7 | 0.220 |
Why?
| Focal Adhesions | 1 | 2002 | 14 | 0.220 |
Why?
| Receptors, Immunologic | 1 | 2002 | 37 | 0.210 |
Why?
| Myocardium | 2 | 2003 | 429 | 0.210 |
Why?
| Rad52 DNA Repair and Recombination Protein | 1 | 2022 | 3 | 0.210 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2003 | 156 | 0.210 |
Why?
| Immunoglobulin Class Switching | 1 | 2022 | 8 | 0.210 |
Why?
| Immunoglobulin D | 1 | 2022 | 4 | 0.210 |
Why?
| Enzyme Activators | 1 | 2002 | 8 | 0.200 |
Why?
| Adrenergic alpha-Agonists | 1 | 2002 | 20 | 0.200 |
Why?
| Biopsy | 2 | 2016 | 582 | 0.200 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 152 | 0.200 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 72 | 0.200 |
Why?
| Middle Aged | 5 | 2019 | 11997 | 0.200 |
Why?
| Escherichia coli Proteins | 1 | 2002 | 56 | 0.200 |
Why?
| Bacterial Proteins | 2 | 2014 | 373 | 0.180 |
Why?
| Tissue Array Analysis | 1 | 2019 | 45 | 0.170 |
Why?
| Sarcoma, Myeloid | 1 | 2019 | 19 | 0.170 |
Why?
| Paraffin Embedding | 1 | 2019 | 53 | 0.170 |
Why?
| Glycosylation | 1 | 2019 | 100 | 0.170 |
Why?
| Adolescent | 3 | 2019 | 6340 | 0.170 |
Why?
| Aged, 80 and over | 2 | 2018 | 3125 | 0.170 |
Why?
| Lung Neoplasms | 2 | 2024 | 605 | 0.170 |
Why?
| Mice | 9 | 2024 | 5720 | 0.160 |
Why?
| Color | 1 | 2018 | 22 | 0.160 |
Why?
| Automation | 1 | 2018 | 17 | 0.160 |
Why?
| Lymphatic Vessels | 1 | 2018 | 46 | 0.160 |
Why?
| Myocytes, Cardiac | 2 | 2013 | 125 | 0.150 |
Why?
| Partial Thromboplastin Time | 1 | 2017 | 12 | 0.150 |
Why?
| Prothrombin Time | 1 | 2017 | 18 | 0.150 |
Why?
| Immunophenotyping | 1 | 2018 | 109 | 0.150 |
Why?
| Failure to Thrive | 1 | 2017 | 18 | 0.150 |
Why?
| Histoplasma | 1 | 2017 | 27 | 0.150 |
Why?
| Clonal Evolution | 1 | 2018 | 56 | 0.150 |
Why?
| Endothelial Cells | 1 | 2019 | 269 | 0.150 |
Why?
| Rare Diseases | 1 | 2017 | 44 | 0.150 |
Why?
| Blood Coagulation | 1 | 2017 | 57 | 0.150 |
Why?
| Vomiting | 1 | 2017 | 74 | 0.150 |
Why?
| Biopsy, Needle | 1 | 2017 | 183 | 0.140 |
Why?
| Gene Expression Regulation | 1 | 2002 | 979 | 0.140 |
Why?
| Young Adult | 2 | 2019 | 3936 | 0.140 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 169 | 0.140 |
Why?
| Animals | 11 | 2024 | 13150 | 0.140 |
Why?
| Neoplasm, Residual | 1 | 2017 | 166 | 0.140 |
Why?
| Risk Assessment | 2 | 2017 | 1262 | 0.130 |
Why?
| Bone Marrow | 1 | 2018 | 362 | 0.130 |
Why?
| Algorithms | 1 | 2019 | 616 | 0.130 |
Why?
| Lung | 1 | 2019 | 480 | 0.130 |
Why?
| Weight Loss | 1 | 2017 | 239 | 0.130 |
Why?
| Flow Cytometry | 1 | 2018 | 470 | 0.130 |
Why?
| V(D)J Recombination | 1 | 2015 | 4 | 0.130 |
Why?
| Pyridines | 2 | 2008 | 130 | 0.120 |
Why?
| Aged | 3 | 2019 | 9272 | 0.120 |
Why?
| Cells, Cultured | 4 | 2013 | 1571 | 0.120 |
Why?
| Fatal Outcome | 1 | 2014 | 195 | 0.120 |
Why?
| Neoplasm Metastasis | 2 | 2012 | 231 | 0.120 |
Why?
| Protein Kinases | 1 | 2014 | 72 | 0.110 |
Why?
| Polymerase Chain Reaction | 1 | 2015 | 455 | 0.110 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 76 | 0.110 |
Why?
| Transcription Factors | 2 | 2014 | 563 | 0.110 |
Why?
| Rh Isoimmunization | 1 | 2012 | 2 | 0.110 |
Why?
| Rho(D) Immune Globulin | 1 | 2012 | 2 | 0.110 |
Why?
| Pregnancy Complications, Hematologic | 1 | 2012 | 15 | 0.100 |
Why?
| Chromogranins | 1 | 2012 | 5 | 0.100 |
Why?
| Synaptophysin | 1 | 2012 | 7 | 0.100 |
Why?
| Vimentin | 1 | 2012 | 32 | 0.100 |
Why?
| Follow-Up Studies | 1 | 2017 | 2179 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 143 | 0.100 |
Why?
| Virulence Factors | 1 | 2012 | 78 | 0.100 |
Why?
| Antineoplastic Agents | 2 | 2012 | 1172 | 0.100 |
Why?
| Leukemia, Myelomonocytic, Chronic | 1 | 2011 | 17 | 0.100 |
Why?
| Leukocytosis | 1 | 2011 | 12 | 0.100 |
Why?
| Chimerism | 1 | 2011 | 7 | 0.100 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2012 | 188 | 0.100 |
Why?
| Infant | 2 | 2017 | 3551 | 0.090 |
Why?
| Adult | 3 | 2019 | 13160 | 0.090 |
Why?
| Plateletpheresis | 1 | 2010 | 7 | 0.090 |
Why?
| Blotting, Western | 2 | 2002 | 602 | 0.090 |
Why?
| Telomerase | 1 | 2010 | 27 | 0.090 |
Why?
| Blood Preservation | 1 | 2010 | 26 | 0.090 |
Why?
| Myelodysplastic Syndromes | 1 | 2011 | 80 | 0.090 |
Why?
| Chromosomes, Human, Pair 8 | 1 | 2010 | 14 | 0.090 |
Why?
| Retrospective Studies | 2 | 2019 | 6117 | 0.090 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2010 | 19 | 0.090 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 2010 | 19 | 0.090 |
Why?
| Keratinocytes | 1 | 2011 | 89 | 0.090 |
Why?
| Blood Proteins | 1 | 2010 | 82 | 0.090 |
Why?
| Bone Marrow Cells | 1 | 2011 | 192 | 0.090 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2011 | 115 | 0.090 |
Why?
| Anaphylaxis | 1 | 2010 | 71 | 0.090 |
Why?
| Staphylococcus aureus | 1 | 2012 | 326 | 0.080 |
Why?
| Mice, Transgenic | 3 | 2013 | 555 | 0.080 |
Why?
| Treatment Outcome | 2 | 2017 | 5138 | 0.080 |
Why?
| Neural Tube Defects | 1 | 2008 | 32 | 0.080 |
Why?
| Copper | 1 | 2008 | 43 | 0.080 |
Why?
| Thoracic Wall | 1 | 2008 | 9 | 0.080 |
Why?
| Benzenesulfonates | 1 | 2008 | 12 | 0.080 |
Why?
| Neurilemmoma | 1 | 2008 | 24 | 0.080 |
Why?
| Nerve Sheath Neoplasms | 1 | 2008 | 20 | 0.080 |
Why?
| Blood Platelets | 1 | 2010 | 245 | 0.080 |
Why?
| Atherosclerosis | 1 | 2010 | 214 | 0.080 |
Why?
| Skin | 1 | 2011 | 407 | 0.080 |
Why?
| Rats | 3 | 2003 | 3300 | 0.070 |
Why?
| Mice, Knockout | 3 | 2022 | 841 | 0.070 |
Why?
| Inflammation | 1 | 2010 | 604 | 0.070 |
Why?
| Isoenzymes | 2 | 2003 | 168 | 0.060 |
Why?
| Infant, Newborn | 1 | 2012 | 2744 | 0.060 |
Why?
| Pregnancy | 1 | 2012 | 2584 | 0.060 |
Why?
| Animals, Newborn | 2 | 2003 | 366 | 0.060 |
Why?
| Heart | 2 | 2003 | 326 | 0.060 |
Why?
| Uridine Triphosphate | 1 | 2003 | 15 | 0.060 |
Why?
| Catheter-Related Infections | 2 | 2014 | 50 | 0.060 |
Why?
| Chromosome Aberrations | 2 | 2018 | 298 | 0.050 |
Why?
| Disease Models, Animal | 3 | 2014 | 1451 | 0.050 |
Why?
| Pertussis Toxin | 1 | 2002 | 11 | 0.050 |
Why?
| Biopolymers | 1 | 2002 | 14 | 0.050 |
Why?
| Virulence | 2 | 2014 | 171 | 0.050 |
Why?
| Receptors, Scavenger | 1 | 2002 | 29 | 0.050 |
Why?
| Macrophages, Peritoneal | 1 | 2002 | 31 | 0.050 |
Why?
| Scavenger Receptors, Class A | 1 | 2002 | 39 | 0.050 |
Why?
| Bacteremia | 2 | 2014 | 92 | 0.050 |
Why?
| Cell Adhesion | 1 | 2002 | 158 | 0.050 |
Why?
| Atrial Natriuretic Factor | 1 | 2002 | 21 | 0.050 |
Why?
| Adrenergic alpha-1 Receptor Agonists | 1 | 2002 | 3 | 0.050 |
Why?
| Thymidine | 1 | 2002 | 18 | 0.050 |
Why?
| Actins | 1 | 2002 | 118 | 0.050 |
Why?
| Blotting, Northern | 1 | 2002 | 109 | 0.050 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 33 | 0.050 |
Why?
| MAP Kinase Kinase 4 | 1 | 2002 | 29 | 0.050 |
Why?
| Primary Cell Culture | 1 | 2022 | 61 | 0.050 |
Why?
| Genes, Reporter | 1 | 2002 | 89 | 0.050 |
Why?
| Gene Knockdown Techniques | 1 | 2022 | 106 | 0.050 |
Why?
| Adenosine Triphosphate | 1 | 2003 | 234 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2002 | 122 | 0.050 |
Why?
| Rats, Sprague-Dawley | 2 | 2003 | 1595 | 0.050 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 96 | 0.050 |
Why?
| Recombination, Genetic | 1 | 2022 | 108 | 0.050 |
Why?
| Enzyme Activation | 1 | 2002 | 276 | 0.050 |
Why?
| Transfection | 1 | 2002 | 357 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 292 | 0.050 |
Why?
| Imidazoles | 1 | 2002 | 119 | 0.050 |
Why?
| B-Lymphocytes | 1 | 2022 | 170 | 0.050 |
Why?
| Methionine | 1 | 2002 | 135 | 0.050 |
Why?
| Repressor Proteins | 1 | 2002 | 151 | 0.050 |
Why?
| Phosphorylation | 1 | 2022 | 536 | 0.050 |
Why?
| Carrier Proteins | 1 | 2002 | 304 | 0.040 |
Why?
| Cell Line | 1 | 2002 | 1002 | 0.040 |
Why?
| Heart Ventricles | 1 | 2002 | 248 | 0.040 |
Why?
| Fibroblasts | 1 | 2002 | 343 | 0.040 |
Why?
| Cell Line, Tumor | 1 | 2024 | 1402 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2002 | 477 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2022 | 436 | 0.040 |
Why?
| DNA | 1 | 2002 | 545 | 0.040 |
Why?
| Pathology, Molecular | 1 | 2018 | 22 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2018 | 177 | 0.040 |
Why?
| Animals, Outbred Strains | 1 | 2012 | 11 | 0.030 |
Why?
| Daptomycin | 1 | 2012 | 29 | 0.030 |
Why?
| Prognosis | 1 | 2017 | 1952 | 0.030 |
Why?
| Cell Survival | 1 | 2013 | 598 | 0.020 |
Why?
| Microbial Sensitivity Tests | 1 | 2012 | 271 | 0.020 |
Why?
| Karyotyping | 1 | 2011 | 83 | 0.020 |
Why?
| Biofilms | 1 | 2012 | 180 | 0.020 |
Why?
| Isotonic Solutions | 1 | 2010 | 19 | 0.020 |
Why?
| Platelet Transfusion | 1 | 2010 | 28 | 0.020 |
Why?
| Time Factors | 1 | 2017 | 2912 | 0.020 |
Why?
| P-Selectin | 1 | 2010 | 32 | 0.020 |
Why?
| Receptors, LDL | 1 | 2010 | 66 | 0.020 |
Why?
| Sodium Chloride | 1 | 2010 | 57 | 0.020 |
Why?
| Platelet Aggregation | 1 | 2010 | 71 | 0.020 |
Why?
| Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 13 | 0.020 |
Why?
| Platelet Activation | 1 | 2010 | 46 | 0.020 |
Why?
| Hypersensitivity | 1 | 2010 | 77 | 0.020 |
Why?
| Staphylococcal Infections | 1 | 2012 | 269 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2010 | 191 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2010 | 170 | 0.020 |
Why?
| Coronary Vessels | 1 | 2010 | 152 | 0.020 |
Why?
| NF-kappa B | 1 | 2010 | 314 | 0.020 |
Why?
| Short Bowel Syndrome | 1 | 2008 | 16 | 0.020 |
Why?
| Parenteral Nutrition, Total | 1 | 2008 | 31 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2010 | 388 | 0.020 |
Why?
| Phenylurea Compounds | 1 | 2008 | 15 | 0.020 |
Why?
| Niacinamide | 1 | 2008 | 22 | 0.020 |
Why?
| Enterocolitis, Necrotizing | 1 | 2008 | 35 | 0.020 |
Why?
| Radiography, Thoracic | 1 | 2008 | 66 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 743 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2008 | 202 | 0.020 |
Why?
| Mutation | 1 | 2011 | 1293 | 0.020 |
Why?
| Brain Neoplasms | 1 | 2008 | 286 | 0.020 |
Why?
| Purinergic P1 Receptor Antagonists | 1 | 2003 | 2 | 0.010 |
Why?
| Purinergic P2 Receptor Antagonists | 1 | 2003 | 4 | 0.010 |
Why?
| Phospholipase C gamma | 1 | 2003 | 4 | 0.010 |
Why?
| Adrenergic Agonists | 1 | 2003 | 8 | 0.010 |
Why?
| Phospholipase C beta | 1 | 2003 | 2 | 0.010 |
Why?
| Type C Phospholipases | 1 | 2003 | 14 | 0.010 |
Why?
| Phenylephrine | 1 | 2003 | 34 | 0.010 |
Why?
| Perfusion | 1 | 2003 | 47 | 0.010 |
Why?
| Hypertrophy | 1 | 2003 | 50 | 0.010 |
Why?
| Vasoconstriction | 1 | 2003 | 54 | 0.010 |
Why?
| Cyclic AMP | 1 | 2003 | 90 | 0.010 |
Why?
| Aorta | 1 | 2003 | 160 | 0.010 |
Why?
| Electrocardiography | 1 | 2003 | 253 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2008 | 1533 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2003 | 1374 | 0.010 |
Why?
|
|
Post's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|